MicroRNAs (miRNAs) play key roles in inflammatory responses of macrophages. However, the function of miRNAs in macrophage-derived foam cell formation is unclear. Here, we investigated the role of miRNAs in macrophage-derived foam cell formation and atherosclerotic development.
Introduction
Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids and inflammatory cells in the vessel wall. 1 Monocytes respond to chemotactic factors and cytokines produced by vascular endothelial cells, smooth muscle cells, and infiltrated cells, by migrating from the peripheral blood into the arterial intima and differentiating into macrophages. 2, 3 In this process, low density lipoproteins (LDL), which are the major transporters of both cholesterol and fatty acids, are activated by reactive oxygen species (ROS), and this leads to formation of oxidized LDL (oxLDL). 4 Finally, macrophages take up these oxLDL to form lipid-laden 'foam cells', the hallmark of an early atherosclerotic lesion. MicroRNAs (miRNAs) are a class of 19-25 nt non-coding RNAs that comprise a fundamental layer of post-transcriptional regulation of gene expression. Recent reports show that miRNAs are present in various biological fluids, including blood, and serve potentially as good diagnostic markers, prognostic markers, or therapeutic targets. 5, 6 The functions of miRNAs have been found to extend to both physiological and pathological conditions. 7, 8 Several miRNAs, including miR-155, miR-146, miR-125b, and miR-33, have a role in the inflammatory responses of the immune system and lipid metabolism. 9, 10 In particular, miR-155, which in the genome, is located within a region known as the B-cell integration cluster (BIC), plays a key role in innate immunity. 11 A broad range of inflammatory factors in macrophages, including oxLDL, can induce the expression of miR-155, 9 which in turn regulates the expression of inflammatory factors to enhance cellular inflammatory effects. 12 A recent report shows that loss of miR-155 in atherosclerotic ApoE
mice decreases the expression of the chemokine CCL2 by targeting BCL6 and represses the recruitment of monocytes to atherosclerotic lesions in advanced atherosclerosis. 13 In addition, in situ results
showed that miR-155 is mainly expressed in macrophages and SMCs in late atherosclerotic lesions, especially, lesional macrophages are an abundant source of miR-155. 13 However, the role of miR-155 in the formation of macrophage-derived foam cells during early atherogenesis has not been defined. HMG box-transcription protein1 (HBP1) contains a putative HMG box domain and is a transcriptional repressor. 14, 15 Investigations in tumour cell lines demonstrated that HBP1 functions as a proliferation regulator by inhibiting oncogenic pathways. 16 Recently, HBP1 has been shown to decrease ROS production by repressing the expression of p47 phox in endothelial cells 17 or to suppress the expression of the macrophage migration inhibitory factor (MIF), 18 suggesting that HBP1
could be involved in atherosclerotic development. Yin Yang1 (YY1) is a ubiquitously expressed transcription factor that interacts with histone acetyltransferases and deacetylases to activate or suppress gene transcription and is also involved in the inflammation of the immune system. 19 -21 Recent study shows that YY1 plays an important role in the transcriptional regulation of cholesterol-inducible inflammation in the liver. 22 In macrophages, YY1 can repress the promoters of pro-atherogenic genes, includingcytokinesand growth factors. 23 However, the role of YY1 in the pathogenesis of atherosclerosis remains unclear.
In this study, we report that elevated miR-155 enhances oxLDLinduced foam cell formation by targeting HBP1, and that the expression of miR-155 is regulated negatively by the YY1/HDACs complex. Silencing of miR-155 in a high-fat diet (HFD)-fed ApoE 2/2 mice by injecting antagomiR-155 decreased effectively the lipid-laden macrophages and the formation of atherosclerotic plaques. In patients with coronary heart disease (CHD), the expression of miR-155 in CD14 + monocytes was up-regulated and correlated well with pro-atherosclerotic factors expression. These results suggest that miR-155 is a macrophage-derived foam cell formation-associated miRNA that functions in the early atherosclerosis.
Methods
Comprehensive methods are available in the Supplementary material online, Data
Results
3.1 MiR-155 is increased in the plasma of atherosclerotic ApoE 2/2 mice and is induced by oxLDL in macrophages
To explore whether miRNAs are involved in atherogenesis, 15 miRNAs relevant to cardiovascular diseases were detected in the plasma of experimental mice using qRT-PCR. Among them, the expression of miR-155 was increased most significantly in the plasma of HFD-fed ApoE 2/2 mice compared with normal diet (ND)-fed ApoE 2/2 mice, and miR-146b-5p was also increased greatly ( Figure 1A) . We further showed that miR-155 expression was much higher in lipid-laden macrophages isolated from HFD-fed ApoE 2/2 mice than that isolated from ND-fed ApoE 2/2 mice ( Figure 1B and see Supplementary material online, Figure S1 ). Next, macrophages were isolated directly from WT mice and then treated with oxLDL. Expression of miR-155 was the most significantly increased miRNA in all six miRNAs examined in both cell lyses ( Figure 1C ) and supernatants ( Figure 1D ), suggesting that circulating miR-155 in the plasma could derive from the secretion of macrophages induced by oxLDL. To investigate the expression dynamics of miR-155, Raw264.7 cells were treated with oxLDL or native LDL at indicated dose and time. The expression of miR-155 by oxLDL, but not native LDL stimulation was increased significantly in time-and dosedependent manner ( Figure 1E and F ) . Furthermore, Raw264.7 cells were pre-treated with b-carotene and ascorbic acid, which are known as antioxidants, and then treated by oxLDL. The results showed that oxLDL induced expression of miR-155 in macrophages by increasing oxidative stress of the cells (see Supplementary material online, Figure  S2 ). Furthermore, Raw264.7 cells were stimulated by oxLDL over a 16-h time course. Pri-miR-155 (BIC) was induced, rapidly reached its peak at 2 h, and then decreased. In contrast, miR-155 continued to increase until 16 h ( Figure 1G ), suggesting that oxLDL induces miR-155 expression at the transcription level. Together, these suggest that miR-155 correlates with the pathogenesis of atherosclerosis, and that the level of miR-155 expression in macrophages is induced mainly by oxLDL not native LDL.
HBP1 is a functional target of miR-155
Lipid uptake and ROS production of macrophages play a central role in macrophage-derived foam cell formation. 1 To explore whether miR-155 affects these two aspects during foam cell formation, we firstly assessed genes involved in oxLDL uptake and ROS production 1 -3 in Raw264.7 cells by overexpression of miR-155 (see Supplementary material online, Figure S3A ). Expression of CD36, SR-A, CD68, SR-B, p20 phox , and p67 phox mRNA was not altered, whereas MIF and p47 phox mRNA expression was higher (see Supplementary material online, Figure S3B ). Furthermore, Raw264.7 cells were transfected with miR-155 or anti-miR-155 at the indicated dose, and then incubated with DiI-oxLDL. Confocal imaging and FACS results showed that overexpression of miR-155 in Raw264.7 cells enhanced lipid uptake at a dosedependent manner. Conversely, inhibition of miR-155 presented the opposite effects ( Figure 2A and see Supplementary material online, Figure S3C -F). Next, the ROS assay showed that overexpression of miR-155 in oxLDL-induced Raw264.7 cells enhanced ROS production, while silencing miR-155 in oxLDL-induced Raw264.7 cells inhibited this effect ( Figure 2B ). Collectively, these findings suggest that elevated miR-155 promotes the oxLDL-induced foam cell formation.
To identify potential targets of miR-155, we applied several miRNA targets prediction algorithms, including Targetscan  24 and RNAhybrid   25 algorithms, five genes involved in inflammatory signal pathways and showed a relatively strong binding with miR-155 were identified, and were selected for further luciferase reporter screening (see Supplementary material online, Figure S4 ). Among the five reporters, miR-155 repressed the one carrying HBP1 3 ′ UTR with two putative miR-155-binding elements that were labelled as A and B (see Supplementary material online, Figure S5A ). Interestingly, the nucleotides complementary to the miR-155 seed sequences were conserved highly among human, mouse, and rat (see Supplementary material online, Figure S5B ). To figure out which one of the two putative binding sites in HBP1 3 ′ UTR was responsible for the suppression, site-directed mutagenesis was performed to destroy them individually. Results showed that site B mutation almost rescued the luciferase activity suppressed by miR-155. While site A mutation had no effect on the luciferase activity suppressed by miR-155, indicating that the luciferase activity suppression conferred by miR-155 was mediated by site B, not site A ( Figure 2C ). Consistent with the reporter assays, the expression of HBP1 was decreased in Raw264.7 cells by overexpression of miR-155 ( Figure 2D ). Conversely, the expression of HBP1 was increased in oxLDL-induced Raw264.7 cells by inhibiting miR-155 ( Figure 2E) . Further, the expression of MicroRNA-155 promotes foam cell formation by targeting HBP1 Figure S6A-D) . These results indicate that HBP1 is a bona fide target of miR-155. To further examine whether HBP1 is a functional target of miR-155 during foam cell formation, Raw264.7 cells were transfected with the siHBP1 or HBP1 overexpression vector. Expression of HBP1 was decreased by siHBP1 transfection and on the contrary up-regulated by HBP1 overexpression vector transfection ( Figure 3A) . Overexpression of HBP1 could rescue the level of HBP1 protein decreased by miR-155 overexpression ( Figure 3B) . Next, overexpression of HBP1 decreased lipid uptake and ROS production in oxLDL-induced Raw264.7 cells, while knockdown of HBP1 increased significantly lipid uptake and ROS production as shown by confocal imaging, Oil Red O staining, and ROS assay, respectively. Importantly, overexpression of HBP1 reversed the effects caused by overexpression of miR-155 on lipid uptake and ROS production ( Figure 3C and D and see Supplementary material online, Figure S7 ). To gain more insight into the underlying molecular events of HBP1 regulation of foam cell formation, we examined the expression of MIF and p47 phox in oxLDL-Raw264.7 cells by knockdown of HBP1 or overexpression of miR-155. As shown in Figure 3E - 
YY1/HDAC2/4 complex suppresses foam cell formation by repressing expression of miR-155
To control the formation of macrophage-derived foam cell in atherogenesis, it is necessary to identify genes that inhibit the expression of miR-155 in macrophages, and the transcriptional repressors of pri-miR-155 may be a good candidate. Using a TRANSFAC tool, 26 four transcriptional repressors binding potentially to the promoter of pri-miR-155 were identified, then these four repressors were selected for further luciferase reporters screening. Among these repressors, knockdown of YY1 19 increased significant activity of the luciferase reporter of pri-miR-155 (see Supplementary material online, Figure S8 ). Interestingly, there were three YY1 binding sites in the promoter region of pri-miR-155. These YY1 binding sites (referred to as A, B, and C) were located in the conserved region (21 to 22.7 kb) upstream of BIC/pri-miR-155 (see Supplementary material online, Figure S9A and B). Next, WT or three MUT (YY1 A, B, or C binding site mutated individually) reporter plasmids were transfected, respectively, into Raw264.7 cells along with siYY1 or YY1 expression plasmids. Results showed that luciferase activity of MUT B and, in particular, MUT C reporter plasmid were significantly increased (compared with WT) in Raw264.7 cells in the context of both control transfection and YY1 silencing or overexpression ( Figure 4A ), indicating that sites B and C in upstream of miR-155 were potential binding sites of YY1. Next, the electrophoretic mobility shift assay (EMSA) was carried out in Raw264.7 cells treated with oxLDL at the indicated time. Result showed that sites B and C both produced protein-DNA binding complexes at 30 min, especially, site C was the most competent YY1 binding site (see Supplementary material online, Figure S9C ). To further determine whether YY1 binds to the promoter region of pri-miR-155 by using site C, a supershift EMSA was performed in nuclear extract of Raw264.7 cells treated by oxLDL for 30 min, and results showed that site C probe produced with YY1 antibody-protein binding complexes ( Figure 4B) . These results suggest that site C mediates mainly the suppression of miR-155 conferred by YY1, and site B is also involved in this process. Moreover, we performed chromatin immune precipitation (ChIP) experiments in Raw264.7 cells to determine whether YY1 binds directly to the pri-miR-155 genomic locus. Results showed that YY1 binds directly to the promoter region of pri-miR-155 in oxLDL-induced macrophages at the indicated time ( Figure 4C and see Supplementary material online, Figure S9D ). Furthermore, overexpression of YY1 decreased the expression of miR-155 by 2.5-fold in oxLDL-induced Raw264.7 cells. Conversely, knockdown of YY1 significantly increased the expression of miR-155 ( Figure 4D and E) . These results indicate that YY1 is a new transcriptional repressor of miR-155. Previous studies have demonstrated that histone deacetylase HDAC1/2/3/4 interacts with YY1 to repress gene transcription. 20, 21 To explore whether YY1 interacts with HDACs to repress the expression of pri-miR-155 synergistically, Raw264.7 cells were pre-treated with trichostatin A (TSA) or sodium butyrate (NaB), which are known as HDACs inhibitors, followed by oxLDL treatment. As shown in Figure 4F and G, TSA or NaB treatment activated the expression of miR-155. We further explored which members of HDACs are involved in transcriptional regulation of miR-155 expression. Results showed that the expression of miR-155 was enhanced in oxLDL-induced Raw264.7 cells by knockdown of HDAC2 or HDAC4 and was not altered by knockdown of HDAC1 or HDAC3 ( Figure 4H and see Supplementary material online, Figure S10 ). Further analysis showed that the expression of miR-155 was up-regulated much more in oxLDL-induced Raw264.7 cells by knockdown of both HDAC2 and HDAC4 rather than by knockdown of HDAC2 or HDAC4 individually ( Figure 4H) . Together, these results indicate that YY1/HDAC2/4 complex negatively regulates the expression of miR-155.
To explore whether YY1/HDACs regulates formation of oxLDLinduced foam cell, we firstly examined the expression of HBP1 in oxLDL-induced Raw264.7 cells by knockdown of YY1 or TSA treatment. Results showed that knockdown of YY1 or TSA treatment decreased the expression of HBP1 ( Figure 4I and see Supplementary material online, Figure S11A ). Next, lipid uptake of Raw264.7 cells was examined by knockdown of YY1 or TSA treatment. Confocal imagings showed that knockdown of YY1 or TSA treatment increased lipid uptake in DiI-oxLDL-induced Raw264.7 cells. Inhibition of miR-155 reversed obviously the effects caused by knockdown of YY1 or TSA treatment on lipid loading in macrophages (see Supplementary material online, Figure S11B and C). Moreover, we found that knockdown of YY1 increased expression of p47 phox and ROS production in oxLDL-induced Raw264.7 cells (see Supplementary material online, Figure S11D and E). Together, these results indicate that YY1/ HDAC2/4 complex inhibits oxLDL-induced foam cell formation by suppressing miR-155 expression.
AntagomiR-155 protects mice against atherosclerosis
To address the role of miR-155 in atherosclerosis in vivo, 6-week-old male ApoE 2/2 mice were fed with HFD, and then injected with control antagomiR or antagomiR-155 via the tail vein. Results showed that the expression of miR-155 in macrophages from antagomiR-155-injected ApoE 2/2 mice was decreased effectively ( Figure 5A ). qRT-PCR results showed that the level of HBP1 mRNA expression was increased significantly in atherosclerotic roots of ApoE 2/2 mice, whereas the level of TNF-a and IL-16 mRNA expression were decreased were decreased effectively ( Figure 5C ). Of note, there were no differences in plasma total triglycerides and cholesterol, body weight, and collagen contents of atherosclerotic plaques between antagomiRand antagomiR-155-injected ApoE 2/2 mice (see Supplementary MicroRNA-155 promotes foam cell formation by targeting HBP1 material online, Figure S12A -D) . However, we found that levels of TNF-a and IL-6 expression in the plasma of antagomiR-155-injected ApoE 2/2 mice were decreased ( Figure 5D) . Importantly, the atherosclerotic plaques in the en face thoraco-abdominal aorta and in serial cross sections of aortic roots were decreased obviously in antagomiR-155-injected ApoE 2/2 mice compared with that of antagomiR-injected ApoE 2/2 mice ( Figure 5E and F ) . Furthermore, CD68 staining showed that macrophages accumulation in the thoraco-abdominal aorta of aortic roots was decreased obviously in antagomiR-155-injected ApoE 2/2 mice ( Figure 5G ).These results indicate that silencing of miR-155 by antagomiR-155 delivery alleviated atherosclerotic lesions in mice.
3.5 MiR-155 expression was significantly increased in CD14 1 monocytes from patient with coronary heart disease To further assess the clinical significance of miR-155, we examined its expression in CD14
+ monocytes isolated from patients with CHD and healthy controls (see Supplementary material online, Table S1 ). qRT-PCR results showed that miR-155 expression was increased considerably in CD14 + monocytes isolated from patients with CHD compared with that of healthy controls ( Figure 6A ). We further examined the expression of several downstream genes of miR-155. Consistent with the up-regulation of miR-155, the level of HBP1 mRNA expression was decreased significantly in CD14 + monocytes from patients with CHD ( Figure 6B ). The levels of TNF-a and IL-6 mRNA expression, regulated by miR-155, 12 were increased in CD14 + monocytes from patients with CHD ( Figure 6C and D) . Furthermore, linear correlation analysis
showed that TNF-a and IL-6 mRNA expression correlated with the expression of miR-155 in CD14 + monocytes from patients ( Figure 6E and F ). These results indicate that miR-155 expression in CD14 + monocytes from patients with CHD is up-regulated and correlates with proatherosclerotic factor production.
Discussion
In this study, we reported that oxLDL-induced miR-155 elevation was critically involved in atherosclerotic development by regulating foam cell formation. We have proved that miR-155, by direct repression of HBP1 expression, promoted lipid uptake and ROS production of macrophages to enhance foam cell formation in vitro, and that the YY1/HDACs complex negatively regulated miR-155 expression. Moreover, inhibition of miR-155 relieved considerably atherosclerotic plaques in the ApoE 2/2 mouse model. Importantly, we showed that miR-155 expression in CD14 + monocytes was up-regulated in patients with CHD, suggesting that miR-155 could be a potential therapeutic target for atherosclerosis.
HBP1 is involved in cell-cycle progression, apoptosis, and terminal differentiation. 15, 16 The present study identified that HBP1 which was low in lipid-laden macrophages, was a novel target of miR-155 to mediate oxLDL-induced increase of lipid uptake and ROS production of macrophages. Repression of HBP1 by miR-155 transforms macrophages into foam cells and this is a new pathway in initiation of atherosclerosis. Our work also showed that HBP1 expression was down-regulated in CD14 + monocytes from patients with CHD, as well as in macrophages from an atherosclerotic ApoE 2/2 model, in which miR-155 expression was up-regulated. Further, gain-and loss-of-function analyses showed that HBP1 expression was miR-155 dependent to function on ROS production and lipid uptake. Genes involved in downstream of HBP1 remains to be determined. Recent studies reported that HBP1 inhibits ROS production by repression of p47 phox which is involved in the pathogenesis of atherosclerosis; 18, 27 and that HBP1 reduces lipid uptake by repression of MIF, 19 which is critical for oxLDL uptake of macrophages. 28, 29 Our results also showed that miR-155 (through HBP1) up-regulated expression of p47 phox and promoted up-regulation of MIF. Collectively, these results suggest that p47 phox and MIF may act downstream of HBP1 to enhance ROS production and promote lipid uptake, respectively. However, whether cell type-specific modulation of HBP1, especially in macrophages, would affect atherogenesis in vivo warrants further investigations. Recent studies have shown that several transcriptional factors, including AP-1, C-myb, and NF-kB, up-regulated the expression of miR-155 in the immune system, 12, 30, 31 but the transcriptional repressors of miR-155 remain little reported. Our study found that in oxLDL-activated macrophages, YY1 was recruited and bonded to the promoter region of pri-miR-155 and further repressed the expression of miR-155. Thus, YY1 is a novel transcriptional repressor of miR-155 expression.
Further analysis demonstrated that YY1 is required for the recruitment of HDACs to the promoter region of pri-miR-155 to inhibit the expression of miR-155 synergistically. Our data also showed that oxLDL inhibited obviously HDAC activity in Raw264.7 cells (see Supplementary material online, Figure S13 ). This suggests a potential mechanism in that the YY1/HDACs' complex regulates the formation of foam cell by suppressing the expression of miR-155: oxLDL firstly activates the expression of miR-155 in macrophages, then the YY1/HDACs complex is recruited to the promoter region of pri-miR-155 to restrain overactivation of miR-155, and this may prevent macrophages' excessive formation of foam cells. These data suggest that the YY1/HDACs complex could play a protective role in early atherosclerosis. The present study shows that circulating miR-155 was increased significantly in the plasma of HFD-fed ApoE 2/2 mice, in which early atherosclerotic plaques had already formed in the aortic roots. Further results indicate that circulating miR-155 in the plasma could be released from activated macrophages. In vivo silencing of miR-155 in mice by injection antagomiR-155 attenuated substantially lipid-laden macrophages, levels of pro-atherosclerotic factors in the plasma, and the formation of atherosclerotic plaques in atherosclerotic mice. This is in contrast to the previous result, which reports increased lipid accumulation in THP-1 cells following treatment with a miR-155 inhibitor. 32 Interestingly, our data are supported by a recent work that showed that lesional miR-155 2/2 macrophages accumulated fewer lipids in late atherosclerosis. 13 Together with our results that in human patients with CHD, miR-155 expression correlated well with the expression of pro-atherosclerotic factor and that in a mice model, antagomiR-155 reduced atherosclerotic plaque formation, a conclusion can be drawn that miR-155 is critical for the early atherogenesis and further suggests a prospective clinical application of miR-155 in atherosclerotic disease. Recent studies report that in ECs, miR-155 can regulate the endothelial inflammation in atherosclerosis by targeting AGTR1, thus downregulating the expression of chemokines and the recruitment of leucocytes, and, in T cells, 33 miR-155 is hypothesized to promote Th17 differentiation by targeting a negative regulator of the Th17 pathway, ETS-1. 34 While in macrophages, miR-155 can target BCL6
and up-regulate the expression of CCL2 suppressed by BCL6. In situ hybridization results also show that miR-155 is expressed in macrophages and SMCs of atherosclerotic lesions, 12 and especially, macrophages are an abundant source of miR-155. Interestingly, our results found that elevated miR-155 promoted macrophages-derived foam cell formation in atherogenesis by targeting HBP1, and inhibition of miR-155 by antagomiR-155 considerably relieved macrophage-derived foam cell formation in ApoE 2/2 mouse, and further identified that miR-155 was macrophage-derived foam cell formation-associated miRNA. These findings indicate that miR-155 is critical for the early atherogenesis. However, whether inhibition of miR-155 by antagomiR-155 in ApoE 2/2 mice can affect the expression level of miR-155 in the different cell types in the atherogenesis, and whether inhibition of miR-155 in macrophages contributed a major protective effect in the atherogenesis warrants further investigation with individual cell type conditional knockout approaches.
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